On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.
Completed clinical trials may also have results available. If so, a simple summary of the overall results can be found on the lay summaries page.
You may also find a scientific summary of the results on the US and EU Clinical Trial Registries.
The ‘status’ of participant recruitment is defined as follows:
- Not yet recruiting – recruitment has not started yet
- Recruiting – recruitment is open
- Enrolling by invitation – recruitment is open to a particular population who are invited to participate.
- Active, not recruiting – recruitment is closed, participants are still ongoing in the clinical trial;
- Terminated – the study stopped early.
- Completed – the study ended.
Last Data Refreshed @ 28-Aug-2024 06:11:14 UTC
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 149 clinical trials
Follicular Lymphoma
Refractory Follicular Lymphoma
Tazverik
United States of America (the)
Not Yet Recruiting
A study to assess efficacy and safety of oral tazemetostat in adult participants with relapsed/refractory follicular lymphoma that does not have an “EZH2 gain-of-function” genetic mutation
The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an “EZH2” genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections, but when you have follicular lymphoma, the blood cells can form tumours in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous – 5 – SM D form protocol master data -INT / Version 1 treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. In this study, all participants will receive the study drug. It will be taken by mouth (orally), as a tablet, twice daily. The sizes and number of tumours according to scan results will be collected as well as results of safety tests (such as physical examinations and laboratory tests). The study consists of 3 or 4 periods: ? Screening period may take up to 4 weeks and require at least 1 visit. ? Treatment period will require 2 visits for each of the first 2 months, followed by 1 visit every month for the remainder of the first 6 months, followed by 1 visit every 3 months (except for women of childbearing potential [WOCBP], who will continue to have a visit every month) until unacceptable toxicity, disease progression, or the start of new systemic anticancer therapy, whichever is first. ? Safety follow -up period will last for 1 month after the last dose of tazemetostat, and it will end with 1 visit or telephone call. ? Long -term follow -up period is only for participants who stop taking tazemetostat while their disease continues to respond; this period will last until disease progression, start of new cancer treatment, or death from any cause, whichever is first. Tazemetostat will be provided to participants who tolerate it for as long as their disease does not progress. Participants may be transferred to another study or program after about 2 years for continued treatment with tazemetostat or for long-term follow-up. Patients may withdraw consent to participate at any time.
Primary Sclerosing Cholangitis
ritivixibat
Italy
France
Spain
Poland
Recruiting
Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis
This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC). Detailed Description: The primary goal of this study in participants with PSC who are treated with A3907 is to assess the safety and tolerability of A3907 following repeat doses. Secondary goals include evaluation of the pharmacokinetic properties of A3907 (the study of how the body interacts with A3907 for the entire duration of exposure) and changes in safety parameters via laboratory testing such as liver enzymes, bile acid levels and markers of bile acid synthesis.
Biliary Atresia
Bylvay
Turkey
Germany
Australia
Hungary
Israel
Korea (the Republic of)
Italy
Canada
China
Taiwan (Province of China)
France
United Kingdom of Great Britain and Northern Ireland (the)
United States of America (the)
Spain
Belgium
Netherlands (Kingdom of the)
Poland
Malaysia
New Zealand
Recruiting
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy. Detailed Description: Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Alagille Syndrome
Bylvay
Malaysia
Poland
Netherlands (Kingdom of the)
Belgium
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
France
Italy
Germany
Turkey
Recruiting
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT). Detailed Description: Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Moderate To Severe Upper Facial Lines
IPN10200
Germany
France
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
The purpose of this study is to assess the safety and efficacy profile of increasing doses of IPN10200 in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines. This study will be conducted in three stages. The full study (including all stages) will have a maximum 448 participants. The protocol is currently approved up to stage 1, step 1 and stage 1/ step 2. Stage 1 (phase Ib & II) Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL) Step 2 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport Stage 2 (phase II) – An evaluation of efficacy and safety of IPN10200 in one of the following regions: GL + forehead lines (FHL) or lateral canthal lines (LCL) Stage 3 (phase II) – A safety and efficacy evaluation of IPN10200 in all three regions (GL, FHL and LCL)